Board changes are routine and carry no immediate trading signal. Monitor for any future 8-K or proxy filing that might indicate a shift in strategic direction or governance, but no action warranted from this filing alone.
OCUL drugs
OCUL drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5- T+0 · Nov 9 $6.85entry
- T+1 · 7d ago −3.50%α −3.14% · $6.61
- T+5 · 18h ago −12.26%α −10.57% · $6.01
- T+20 · in 21d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Ocular Therapeutix elected Riad Sherif, M.D. to its board effective November 6, 2026, and received notice that director Seung Suh Hong, Ph.D. will resign effective December 31, 2026. Dr. Hong's resignation is stated as not due to any disagreement with the board or management. This is a routine board composition change with no material financial impact.
Key Facts
- Riad Sherif, M.D. elected to the board as a Class I member, effective November 6, 2026
- Dr. Sherif is CEO of Oculis Holding AG and has prior experience at Novartis, Alcon, and Sanofi
- Dr. Sherif received an option for 88,000 shares at $6.60/share and an RSU award for 28,000 shares, both vesting annually over three years
- Seung Suh Hong, Ph.D. notified the company of his resignation from the board, effective December 31, 2026
- Dr. Hong's resignation is not the result of any disagreement with the board or management
Financial Impact
Standard non-employee director compensation: option for 88,000 shares and RSU for 28,000 shares, aggregate value approximately $765,600 based on $6.60 closing price
Risk Factors
- No material risks identified from this filing
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-124159 |
| Document: 0001104659-26-124159-index-headers.html | 0001104659-26-124159 |
| Document: 0001104659-26-124159-index.html | 0001104659-26-124159 |
| Document: 0001104659-26-124159.txt | 0001104659-26-124159 |
Track record
20 reports on OCUL
4 of 5 bullish or bearish reports moved the stock their way by T+5. Best: +24.88% at T+20 after the Aug 3, 2026 report. 5 of 5 went positive at some point.
Filters
- Nov 10, 20266d ago 3 Neutral 2/10 Entry $6.66 Now $6.01 −9.76% settles Nov 18
- Nov 9, 20267d ago 8-K Neutral 2/10 Viewing Entry $6.85 to $6.01 Now $6.01 −12.26% ▼ −12.26% −10.57% vs SPY
- Nov 9, 20267d ago Press Release Bearish 5/10 Entry $6.85 to $6.01 Now $6.01 +12.26% ▲ +12.26% +10.57% vs SPY
- Nov 5, 202611d ago 144 Neutral 3/10 Entry $6.60 to $6.21 Now $6.01 −8.87% ▼ −5.84% −8.43% vs SPY
- Oct 16, 20264w ago 8-K Neutral 2/10 Entry $6.29 to $6.47 Now $6.01 −4.45% ▲ +2.86% +3.01% vs SPY
- Oct 8, 20265w ago 144 Neutral 2/10 Entry $7.54 to $6.87 Now $6.01 −20.29% ▼ −8.89% −6.92% vs SPY
- Sep 2, 202610w ago Insider Cluster Neutral 4/10 Entry $10.64 to $10.49 Now $6.01 −43.52% ▼ −1.41% −0.26% vs SPY
- Aug 26, 202611w ago Insider Cluster Neutral 3/10 Entry $10.82 to $10.64 Now $6.01 −44.45% ▼ −1.66% −1.93% vs SPY
- Aug 3, 202615w ago 8-K Bullish 7/10 Entry $8.40 to $9.24 Now $6.01 −28.45% ▲ +10.00% +7.97% vs SPY
- Jun 17, 202621w ago Press Release Bullish 6/10 Entry $9.64 to $9.85 Now $6.01 −37.66% ▲ +2.18% +3.22% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers